A short lipidated peptide pulled Nav1.8 pain channels off nerve cell surfaces in a Cell Reports Medicine study. The company says several candidates are now in evaluation.
Recap by typeshit. Full story at Fierce Biotech.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
Robert Lufkin MD shares the observational data: an average 16.1 kg lost at six months among 7,297 women, with 62.7% reporting side effects.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Covers BMI eligibility, who should avoid the drugs and common side effects. Buying direct runs $149 to $299 a month for the Wegovy pill and $299 to $449 for Zepbound.
In 194 adults who moved from injectable semaglutide or tirzepatide to oral semaglutide, 40.7% lost at least 5% more in three months. Data shown at EASD, not yet peer reviewed.
Loading…